Eli Lilly acquires Verve Therapeutics, Inc. for $1B to advance gene-editing therapies like VERVE-102, targeting ASCVD. Click ...

Watching for new technological trends is one of the best ways for keeping up with smart grid innovations, but it’s not easy.

Editas Medicine ( EDIT 12.04%) is a promising clinical-stage company that has captured Wall Street's attention at the ...

For decades, researchers have wondered why some people with risky gene variants go on to develop Parkinson’s disease, while ...

Sarepta’s shares crashed 41% in premarket trading Monday morning to $21.01 after the biotech reported a second death from ...

Glioblastoma has been deadly and hard to treat, but researchers say they’ve made progress with bivalent CAR T-cell therapy ...

Researchers have developed a lung-targeted nanoparticle delivery system for genetic therapies. In a major step forward for ...

Amid a challenging gene editing climate, partnerships between researchers, regulators, and industry remain crucial for ...

Find more information on the Altmetric Attention Score and how the score is calculated. In this study, a novel liver-targeted gene delivery vector was developed by electrostatically coating the ...

A research team has developed a microbubble-based nano-gene delivery platform (BTN MB) that precisely delivers gene ...

Industry experts weigh in on current trends, challenges, and the future of the cell and gene therapy CDMO market. Cell and gene therapies, which fall under the general classification of advanced ...